P
Peter M. Rothwell
Researcher at University of Oxford
Publications - 815
Citations - 77220
Peter M. Rothwell is an academic researcher from University of Oxford. The author has contributed to research in topics: Stroke & Population. The author has an hindex of 134, co-authored 779 publications receiving 67382 citations. Previous affiliations of Peter M. Rothwell include Leicester Royal Infirmary & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis
Journal ArticleDOI
Differences in Vascular Risk Factors Between Etiological Subtypes of Ischemic Stroke Importance of Population-Based Studies
TL;DR: Prevalences of risk factors and stroke subtype differ between hospitalized and nonhospitalized patients with ischemic stroke, which may bias hospital-based risk factor studies, and meta-analysis of population-based studies suggests that vascular risk factors differ between stroke subtypes.
Journal Article
Treating Individuals 1 - External validity of randomised controlled trials: "To whom do the results of this trial apply?"'
TL;DR: A review of the determinants of external validity in trial publications and systematic reviews is usually inadequate, a checklist for clinicians is presented, and recommendations for greater consideration of External validity in the design and reporting of RCTs are made.
Journal ArticleDOI
Systematic Review of the Risks of Carotid Endarterectomy in Relation to the Clinical Indication for and Timing of Surgery
TL;DR: Risk of stroke and death resulting from CEA is highly dependent on the clinical indication, and audits of risk should be stratified accordingly, and patients should be informed of the risk that relates to their presenting event.
Journal ArticleDOI
Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
TL;DR: In patients receiving aspirin-based antiplatelet treatment without routine PPI use, the long-term risk of major bleeding is higher and more sustained in older patients in practice than in the younger patients in previous trials, with a substantial risk of disabling or fatal upper gastrointestinal bleeding.